Clinical phenotypes and quality of life to define post-COVID-19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort.

Publication date: Aug 01, 2023

Lack of specific definitions of clinical characteristics, disease severity, and risk and preventive factors of post-COVID-19 syndrome (PCS) severely impacts research and discovery of new preventive and therapeutics drugs. This prospective multicenter cohort study was conducted from February 2020 to June 2022 in 5 countries, enrolling SARS-CoV-2 out- and in-patients followed at 3-, 6-, and 12-month from diagnosis, with assessment of clinical and biochemical features, antibody (Ab) response, Variant of Concern (VoC), and physical and mental quality of life (QoL). Outcome of interest was identification of risk and protective factors of PCS by clinical phenotype, setting, severity of disease, treatment, and vaccination status. We used SF-36 questionnaire to assess evolution in QoL index during follow-up and unsupervised machine learning algorithms (principal component analysis, PCA) to explore symptom clusters. Severity of PCS was defined by clinical phenotype and QoL. We also used generalized linear models to analyse the impact of PCS on QoL and associated risk and preventive factors. CT registration number: NCT05097677. Among 1796 patients enrolled, 1030 (57%) suffered from at least one symptom at 12-month. PCA identified 4 clinical phenotypes: chronic fatigue-like syndrome (CFs: fatigue, headache and memory loss, 757 patients, 42%), respiratory syndrome (REs: cough and dyspnoea, 502, 23%); chronic pain syndrome (CPs: arthralgia and myalgia, 399, 22%); and neurosensorial syndrome (NSs: alteration in taste and smell, 197, 11%). Determinants of clinical phenotypes were different (all comparisons p

Open Access PDF

Concepts Keywords
Disease COVID-19
February Long-term sequelae
June Post-COVID syndrome
Nct05097677 Prediction model
Orchestra SARS-CoV-2


Type Source Name
disease IDO quality
disease MESH COVID-19
disease MESH syndrome
disease VO LACK
disease VO vaccination
drug DRUGBANK Pidolic Acid
disease IDO symptom
disease MESH chronic pain
disease MESH arthralgia
disease MESH Long Covid
disease MESH Infection
disease VO vaccine
drug DRUGBANK L-Citrulline
disease VO NAP
disease MESH Infectious Diseases
drug DRUGBANK Coenzyme M
disease MESH pulmonary diseases
drug DRUGBANK Oxygen
disease MESH complications
disease IDO acute infection
drug DRUGBANK Etoperidone
disease IDO process
disease VO frequency
disease IDO algorithm
disease VO report
disease MESH vascular diseases
disease MESH breakthrough infection
disease VO population
disease IDO history
disease IDO blood
disease MESH chronic kidney disease
disease MESH HIV infection
pathway REACTOME HIV Infection
disease MESH cardiovascular disease
disease MESH respiratory diseases
disease MESH liver disease
disease MESH neurological disorder

Original Article

(Visited 1 times, 1 visits today)